Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease
Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Eastman, Jacqueline J. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
983 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward - Papakitsou, I. ELSEVIER, 2022, official publication of the American Academy of Allergy, Asthma and Immunology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:140 ; year:2017 ; number:1 ; pages:101-1083 ; extent:983 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jaci.2016.11.023 |
|---|
| Katalog-ID: |
ELV014719312 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV014719312 | ||
| 003 | DE-627 | ||
| 005 | 20230623115322.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaci.2016.11.023 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017001000003.pica |
| 035 | |a (DE-627)ELV014719312 | ||
| 035 | |a (ELSEVIER)S0091-6749(16)32473-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.85 |2 bkl | ||
| 100 | 1 | |a Eastman, Jacqueline J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease |
| 264 | 1 | |c 2017 | |
| 300 | |a 983 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD. | ||
| 650 | 7 | |a aspirin-exacerbated respiratory disease |2 Elsevier | |
| 650 | 7 | |a Group 2 innate lymphoid cells |2 Elsevier | |
| 700 | 1 | |a Cavagnero, Kellen J. |4 oth | |
| 700 | 1 | |a Deconde, Adam S. |4 oth | |
| 700 | 1 | |a Kim, Alex S. |4 oth | |
| 700 | 1 | |a Karta, Maya R. |4 oth | |
| 700 | 1 | |a Broide, David H. |4 oth | |
| 700 | 1 | |a Zuraw, Bruce L. |4 oth | |
| 700 | 1 | |a White, Andrew A. |4 oth | |
| 700 | 1 | |a Christiansen, Sandra C. |4 oth | |
| 700 | 1 | |a Doherty, Taylor A. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Papakitsou, I. ELSEVIER |t Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |d 2022 |d official publication of the American Academy of Allergy, Asthma and Immunology |g Amsterdam [u.a.] |w (DE-627)ELV000021164 |
| 773 | 1 | 8 | |g volume:140 |g year:2017 |g number:1 |g pages:101-1083 |g extent:983 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jaci.2016.11.023 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.85 |j Kardiologie |j Angiologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 140 |j 2017 |e 1 |h 101-1083 |g 983 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
j j e jj jje |
|---|---|
| matchkey_str |
eastmanjacquelinejcavagnerokellenjdecond:2017----:ru2naeypodelaeerietteaamcsiptetwtaprn |
| hierarchy_sort_str |
2017 |
| bklnumber |
44.85 |
| publishDate |
2017 |
| allfields |
10.1016/j.jaci.2016.11.023 doi GBVA2017001000003.pica (DE-627)ELV014719312 (ELSEVIER)S0091-6749(16)32473-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.85 bkl Eastman, Jacqueline J. verfasserin aut Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease 2017 983 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD. aspirin-exacerbated respiratory disease Elsevier Group 2 innate lymphoid cells Elsevier Cavagnero, Kellen J. oth Deconde, Adam S. oth Kim, Alex S. oth Karta, Maya R. oth Broide, David H. oth Zuraw, Bruce L. oth White, Andrew A. oth Christiansen, Sandra C. oth Doherty, Taylor A. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:140 year:2017 number:1 pages:101-1083 extent:983 https://doi.org/10.1016/j.jaci.2016.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 140 2017 1 101-1083 983 045F 610 |
| spelling |
10.1016/j.jaci.2016.11.023 doi GBVA2017001000003.pica (DE-627)ELV014719312 (ELSEVIER)S0091-6749(16)32473-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.85 bkl Eastman, Jacqueline J. verfasserin aut Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease 2017 983 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD. aspirin-exacerbated respiratory disease Elsevier Group 2 innate lymphoid cells Elsevier Cavagnero, Kellen J. oth Deconde, Adam S. oth Kim, Alex S. oth Karta, Maya R. oth Broide, David H. oth Zuraw, Bruce L. oth White, Andrew A. oth Christiansen, Sandra C. oth Doherty, Taylor A. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:140 year:2017 number:1 pages:101-1083 extent:983 https://doi.org/10.1016/j.jaci.2016.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 140 2017 1 101-1083 983 045F 610 |
| allfields_unstemmed |
10.1016/j.jaci.2016.11.023 doi GBVA2017001000003.pica (DE-627)ELV014719312 (ELSEVIER)S0091-6749(16)32473-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.85 bkl Eastman, Jacqueline J. verfasserin aut Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease 2017 983 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD. aspirin-exacerbated respiratory disease Elsevier Group 2 innate lymphoid cells Elsevier Cavagnero, Kellen J. oth Deconde, Adam S. oth Kim, Alex S. oth Karta, Maya R. oth Broide, David H. oth Zuraw, Bruce L. oth White, Andrew A. oth Christiansen, Sandra C. oth Doherty, Taylor A. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:140 year:2017 number:1 pages:101-1083 extent:983 https://doi.org/10.1016/j.jaci.2016.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 140 2017 1 101-1083 983 045F 610 |
| allfieldsGer |
10.1016/j.jaci.2016.11.023 doi GBVA2017001000003.pica (DE-627)ELV014719312 (ELSEVIER)S0091-6749(16)32473-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.85 bkl Eastman, Jacqueline J. verfasserin aut Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease 2017 983 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD. aspirin-exacerbated respiratory disease Elsevier Group 2 innate lymphoid cells Elsevier Cavagnero, Kellen J. oth Deconde, Adam S. oth Kim, Alex S. oth Karta, Maya R. oth Broide, David H. oth Zuraw, Bruce L. oth White, Andrew A. oth Christiansen, Sandra C. oth Doherty, Taylor A. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:140 year:2017 number:1 pages:101-1083 extent:983 https://doi.org/10.1016/j.jaci.2016.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 140 2017 1 101-1083 983 045F 610 |
| allfieldsSound |
10.1016/j.jaci.2016.11.023 doi GBVA2017001000003.pica (DE-627)ELV014719312 (ELSEVIER)S0091-6749(16)32473-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.85 bkl Eastman, Jacqueline J. verfasserin aut Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease 2017 983 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD. aspirin-exacerbated respiratory disease Elsevier Group 2 innate lymphoid cells Elsevier Cavagnero, Kellen J. oth Deconde, Adam S. oth Kim, Alex S. oth Karta, Maya R. oth Broide, David H. oth Zuraw, Bruce L. oth White, Andrew A. oth Christiansen, Sandra C. oth Doherty, Taylor A. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:140 year:2017 number:1 pages:101-1083 extent:983 https://doi.org/10.1016/j.jaci.2016.11.023 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 140 2017 1 101-1083 983 045F 610 |
| language |
English |
| source |
Enthalten in Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward Amsterdam [u.a.] volume:140 year:2017 number:1 pages:101-1083 extent:983 |
| sourceStr |
Enthalten in Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward Amsterdam [u.a.] volume:140 year:2017 number:1 pages:101-1083 extent:983 |
| format_phy_str_mv |
Article |
| bklname |
Kardiologie Angiologie |
| institution |
findex.gbv.de |
| topic_facet |
aspirin-exacerbated respiratory disease Group 2 innate lymphoid cells |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
| authorswithroles_txt_mv |
Eastman, Jacqueline J. @@aut@@ Cavagnero, Kellen J. @@oth@@ Deconde, Adam S. @@oth@@ Kim, Alex S. @@oth@@ Karta, Maya R. @@oth@@ Broide, David H. @@oth@@ Zuraw, Bruce L. @@oth@@ White, Andrew A. @@oth@@ Christiansen, Sandra C. @@oth@@ Doherty, Taylor A. @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000021164 |
| dewey-sort |
3610 |
| id |
ELV014719312 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV014719312</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623115322.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jaci.2016.11.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017001000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV014719312</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0091-6749(16)32473-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.85</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Eastman, Jacqueline J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">983</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">aspirin-exacerbated respiratory disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Group 2 innate lymphoid cells</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cavagnero, Kellen J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Deconde, Adam S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Alex S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karta, Maya R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Broide, David H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zuraw, Bruce L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">White, Andrew A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Christiansen, Sandra C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Doherty, Taylor A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Papakitsou, I. ELSEVIER</subfield><subfield code="t">Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward</subfield><subfield code="d">2022</subfield><subfield code="d">official publication of the American Academy of Allergy, Asthma and Immunology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000021164</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:140</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:101-1083</subfield><subfield code="g">extent:983</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jaci.2016.11.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.85</subfield><subfield code="j">Kardiologie</subfield><subfield code="j">Angiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">140</subfield><subfield code="j">2017</subfield><subfield code="e">1</subfield><subfield code="h">101-1083</subfield><subfield code="g">983</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Eastman, Jacqueline J. |
| spellingShingle |
Eastman, Jacqueline J. ddc 610 bkl 44.85 Elsevier aspirin-exacerbated respiratory disease Elsevier Group 2 innate lymphoid cells Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease |
| authorStr |
Eastman, Jacqueline J. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000021164 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.85 bkl Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease aspirin-exacerbated respiratory disease Elsevier Group 2 innate lymphoid cells Elsevier |
| topic |
ddc 610 bkl 44.85 Elsevier aspirin-exacerbated respiratory disease Elsevier Group 2 innate lymphoid cells |
| topic_unstemmed |
ddc 610 bkl 44.85 Elsevier aspirin-exacerbated respiratory disease Elsevier Group 2 innate lymphoid cells |
| topic_browse |
ddc 610 bkl 44.85 Elsevier aspirin-exacerbated respiratory disease Elsevier Group 2 innate lymphoid cells |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k j c kj kjc a s d as asd a s k as ask m r k mr mrk d h b dh dhb b l z bl blz a a w aa aaw s c c sc scc t a d ta tad |
| hierarchy_parent_title |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
| hierarchy_parent_id |
ELV000021164 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000021164 |
| title |
Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease |
| ctrlnum |
(DE-627)ELV014719312 (ELSEVIER)S0091-6749(16)32473-3 |
| title_full |
Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease |
| author_sort |
Eastman, Jacqueline J. |
| journal |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
| journalStr |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
101 |
| author_browse |
Eastman, Jacqueline J. |
| container_volume |
140 |
| physical |
983 |
| class |
610 610 DE-600 610 VZ 44.85 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Eastman, Jacqueline J. |
| doi_str_mv |
10.1016/j.jaci.2016.11.023 |
| dewey-full |
610 |
| title_sort |
group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease |
| title_auth |
Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease |
| abstract |
Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD. |
| abstractGer |
Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD. |
| abstract_unstemmed |
Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease |
| url |
https://doi.org/10.1016/j.jaci.2016.11.023 |
| remote_bool |
true |
| author2 |
Cavagnero, Kellen J. Deconde, Adam S. Kim, Alex S. Karta, Maya R. Broide, David H. Zuraw, Bruce L. White, Andrew A. Christiansen, Sandra C. Doherty, Taylor A. |
| author2Str |
Cavagnero, Kellen J. Deconde, Adam S. Kim, Alex S. Karta, Maya R. Broide, David H. Zuraw, Bruce L. White, Andrew A. Christiansen, Sandra C. Doherty, Taylor A. |
| ppnlink |
ELV000021164 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.jaci.2016.11.023 |
| up_date |
2024-07-06T22:16:12.480Z |
| _version_ |
1803869667964485632 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV014719312</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623115322.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jaci.2016.11.023</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017001000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV014719312</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0091-6749(16)32473-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.85</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Eastman, Jacqueline J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">983</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">aspirin-exacerbated respiratory disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Group 2 innate lymphoid cells</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cavagnero, Kellen J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Deconde, Adam S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Alex S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karta, Maya R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Broide, David H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zuraw, Bruce L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">White, Andrew A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Christiansen, Sandra C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Doherty, Taylor A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Papakitsou, I. ELSEVIER</subfield><subfield code="t">Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward</subfield><subfield code="d">2022</subfield><subfield code="d">official publication of the American Academy of Allergy, Asthma and Immunology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000021164</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:140</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:101-1083</subfield><subfield code="g">extent:983</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jaci.2016.11.023</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.85</subfield><subfield code="j">Kardiologie</subfield><subfield code="j">Angiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">140</subfield><subfield code="j">2017</subfield><subfield code="e">1</subfield><subfield code="h">101-1083</subfield><subfield code="g">983</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.400402 |